Building on vision to create a better and healthier every day for every woman, Organon
wants to empower women so they can be in full control of their sexual health

Kirkland, Quebec, September 22, 2021 – Organon (NYSE: OGN), a global women’s health
company, will mark this year’s World Contraception Day by launching an awareness campaign
about the global public health issue of unplanned pregnancies. As part of this campaign,
Organon Canada is partnering with the Society of Obstetricians and Gynaecologists of Canada
(SOGC) to ignite a conversation about the surprising rates of unplanned pregnancies in Canada
and the importance to educate woman on how to choose the contraceptive method that fits their
lifestyle the most.

While it is often believed that unplanned pregnancies are no longer an issue in Canada, nearly
50 per cent of pregnancies are unplanned, which demonstrates that this remains an important
public health issue.1 In fact, women in the country spend at least half of their reproductive lives
at risk of an unintended pregnancy.2 Unplanned pregnancy can impact any woman anywhere
— regardless of her social or economic background – and poses a significant cost to individuals
and society, both directly and indirectly. It’s been linked to adverse health outcomes for both the
mother and her infant.3 Worldwide, unplanned pregnancy impacts approximately 121 million
women each year.4 A 2019 study reported that globally, more than 1 billion women have a need
for family planning, but for 270 million of them, that need for modern methods is unmet.5

“Women need to be empowered, through education, empathy and open discussions, to make
the right decisions for their body and decide when they are ready to conceive, whether it’s for
the first time or after a previous pregnancy. We aim to help foster an environment where all
women can have informed conversations with their healthcare professional,” said Amy Cairns,
Vice President of Organon Canada’s Women’s Health Business.

Unintended pregnancies are not just a consequence of unprotected sex, but other factors can
lead to them, including inadequate access or choice to the most appropriate contraceptive
method. When it comes to contraceptive methods, it is not just a one size fits all situation.
Women may benefit from learning more about the different methods available and discuss these
options with their doctor to be able to make an informed decision.

“Canada continues to have a high rate of unintended pregnancies. It is critical that women have
access to contraception methods that best meet their needs and their lifestyle, including options
that have been proven to be safe and effective. Information and education can empower them
to make that choice,” said Dr. Jennifer Blake, Chief Executive Officer of the SOGC.

As a commitment to helping women in their reproductive health journey, Organon Canada and
the SOGC are bringing together women, specialists and doctors in a virtual event on September
28 at 6:30 p.m. EDT to have a conversation about unplanned pregnancy and birth control.
Falling In Love with the Right Contraception will be hosted by Dr. Jennifer Blake, the SOGC’s
CEO, and will feature Dr. Ashley Waddington and Dr. Julie Thorn.

The event will be accessible through the SOGC’s Facebook page, where people are
encouraged to share their perspective to help women take control of their full body and life, by
taking control of their birth control and ultimately reduce unplanned pregnancy.
You can find out more about the event at https://fb.me/e/1bgc4Gy9l

About Organon

            Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from
Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, focused on
improving the health of women throughout their lives. Here for her health, the company has a
portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by
the reproductive health portfolio coupled with an expanding biosimilars business and stable
franchise of established medicines, Organon’s products produce strong cash flows that will
support investments in future growth opportunities in women’s health, including business
development like recently acquired Alydia Health, a medical device company focused on
treating postpartum hemorrhage. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its
scale and presence in fast growing international markets.

            Organon has a global footprint with significant scale and geographic reach, world-class
commercial capabilities, and approximately 9,000 employees with headquarters located in
Jersey City, New Jersey.

For more information, visit organon.com/canada-en/ and connect with us on LinkedIn and
Twitter.

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform
Act of 1995, including, but not limited to, statements about management’s expectations about
Organon’s future prospects. Forward-looking statements may be identified by words such as
“potential,” “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or
words of similar meaning. These statements are based upon the current beliefs and
expectations of Organon’s management and are subject to significant risks and uncertainties. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains;
the impact of pharmaceutical industry regulation and health care legislation in the United States
and internationally; technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory approval;
Organon’s ability to accurately predict its future financial results and performance; Organon’s
ability to accurately predict future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk; dependence on the
effectiveness of Organon’s patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory actions.

Organon does not undertake any obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in Organon’s filings with the Securities and Exchange Commission (“SEC”), including its
registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###

________________________________________

1 The Society of Obstetricians and Gynaecologists of Canada. Unintended pregnancy. Pregnancy info Web site.
https://www.pregnancyinfo.ca/your-pregnancy/special-consideration/unintended-pregnancy/. Accessed September
10, 2021
2 Black A, Guilbert E, Costescu D, et al. Canadian contraception consensus (Part 1 of 4): Chapter 1 – Contraception
in Canada. J Obstet Gynaecol Can. 2015;37(10 Suppl):S5-S12.
3 Oulman E, Kim THM, Yunis K, Tamim H. Prevalence and predictors of unintended pregnancy among women: an
analysis of the Canadian Maternity Experiences Survey. BMC Pregnancy Childbirth. 2015;15:260-267.
4 Bearak J, Painchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152-e1161.
5 Kantorová V, Wheldon MC, Ueffing P, Dasgupta ANZ (2020) Estimating progress towards meeting women’s
contraceptive needs in 185 countries: A Bayesian hierarchical modelling study. PLoS Med. 17(2): e1003026.
*According to Kantorová et. al, modern methods of contraception include female and male sterilization, the
intrauterine device (IUD), the implant, injectables, oral contraceptive pills, male and female condoms, vaginal barrier methods, the lactational amenorrhea method (LAM), emergency contraception and other modern methods such as the contraceptive patch or vaginal ring.

Michael Casia Named as President and Managing Director of the healthcare company committed to leading in the areas of women’s health and biosimilars.

Launching with a commitment to listen to women to understand her health needs and help identify solutions that are urgently needed

Kirkland, Quebec, June 3, 2021 – Organon (NYSE: OGN), today celebrates its launch as the only global company of its size focused on women’s health. Organon Canada, headquartered in Kirkland, Quebec, is led by President and Managing Director Michael Casia. The company aims to become a champion of women’s health in Canada as well as a leader in the field of biosimilars.

“It is a very exciting time for us at Organon Canada, not only to launch a new, multinational healthcare company, but also one that is poised to have a positive impact for Canadians. We are launching with a strong portfolio in women’s health bringing therapeutic options to women in Canada,” explains Michael Casia, President and Managing Director, Organon Canada. “In addition, a key area of focus for us will be our portfolio of biosimilar medicines which we hope will have positive impacts on the sustainability of our healthcare system especially as provinces seek new options to alleviate pressure on healthcare costs. These medicines complement our focus on women’s health and are used to treat conditions that often disproportionally affect women.” Today, the Organon executive leadership team rings the opening bell at the New York Stock Exchange (NYSE) to mark the first day of active trading. Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE sharing powerful perspectives, voices and images.

“If we genuinely want to build a legacy for women and girls in healthcare, we need to make sure that girls and women are at the forefront of research, education and services. Services that are reliable, effective and safe. I welcome the arrival of a new leader focused on pursuing those objectives,” said Solange Tuyishime, President of Elevate International, an organization dedicated to the empowerment of women and girls. Mrs. Tuyishime represented Canada’s Voice in the “Wall of Voices” installation. 

Women everywhere are invited to take the “microphone” to add their voice to the digital “Wall of Voices” at www.hereforherhealth.com.  

Diverse Portfolio will Drive Sustainable Growth

At launch, Organon’s portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 markets, with nearly 80% of its approximately $6.5 billion in annual revenue generated outside the U.S. Organon is well positioned for organic low-to-mid-single digit growth from its 2021 base of business.   

Organon has three core pillars which will benefit from renewed management focus and commercial investment:

  • Women’s Health: Organon Canada will be continuing to launch Nexplanon®, a contraceptive implant, one of the key growth drivers for the company which was made available late last year in Canada. In addition to other contraceptives, the company has medications in fertility as well as hormone replacement therapy.
  • Biosimilars: Biosimilar medicines are an opportunity for Organon Canada to have a positive impact on healthcare in Canada as provinces are looking at these medicines to alleviate healthcare costs. Biosimilars initiatives have been adopted in New Brunswick, Alberta, British Columbia and very recently announced in Quebec. With the planned launch of two Biosimilar medicines in Canada in 2021-22, and three already on the market, Organon Canada aims to become a leader in this area.
  • Established Brands: With over 30 respected medicines in our portfolio, Organon Canada has a diverse offering meeting the needs of patients in Canada with respiratory, cardiovascular diseases as well as in dermatology among other therapy areas. These represent an important part of Organon’s ongoing business.

Women at the Center: Organon’s Approach to Innovation

Organon’s R&D philosophy is to build a business around patient needs, with the goal of identifying and advancing healthcare options for women that enable them to live their best lives every day.

Women have been told for too long that common, often painful conditions such as heavy, painful, and irregular menstrual bleeding, incontinence and menopause, were just a part of life”, said Dr. Parambir Bhangu, Canada Medical Lead at Organon Canada. “Our company’s mission is to change this, in order to make a difference in women’s health every day. We believe an approach centered on the ability to identify diseases earlier, to modify the course of diseases or healthcare conditions and to ultimately improve the quality of life for women at all stages, will provide for a healthier future for women and also for their families and communities.”

The company’s extensive global capabilities in clinical development and patient safety, regulatory and medical affairs make it well-positioned to identify promising drugs, diagnostics and devices with the greatest potential to impact women’s health.

            To learn more about Organon, please visit Organon.ca or interact with us on Twitter and LinkedIn.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA

            This news release of Organon & Co., Jersey City, N.J., USA (the “company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).